USA: A new study published in the Journal of Diabetes and Its Complications suggests that tirzepatide, a novel dual ...

A recent research presented at the ENDO 2025 revealed that high blood sugar levels can impact men's sexual health. The ...

On its clinic website, the supermarket chain said the self-injectable pens can be used once a week to increase a user’s ...

UTMB Health study says erectile dysfunction meds associated with reductions — but not where you might think 😅 Ahmed Humble , Digital Content Producer Published: November 19, 2024 at 11:38 AM ...

Erectile dysfunction (ED) affects up to 66% of diabetic men globally, with risk factors like age, long-term diabetes, and obesity playing a significant role. The study emphasizes the urgent need ...

The study, which involved more than 1,000 prediabetic patients, found that those taking the highest dose of 15 mg lost 23% of their body weight, while those on a placebo lost just 2%. Tirzepatide is ...

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period ...

Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity. PR Newswire . Thu, Aug 1, 2024, 6:45 AM 19 min read.

A new head-to-head study of tirzepatide versus semaglutide for weight loss in people living with obesity, but not diabetes, shows that over 72 weeks tirzepatide results in an average weight loss ...